Clarametyx Biosciences

We are honored to announce a strategic investment by the Kineticos Life Sciences AMR Accelerator Fund ("KAMRA Fund") to fund our continued momentum. We welcome KAMRA Venture Partner Douglas Thomson to our Board of Directors. Read today's announcement here:

Clarametyx CEO David V. Richards spoke with Carrie Ghose at Columbus Business First about our latest advances with our anti-biofilm platform, and specifically the new grant we've received to advance the technology in a vaccine approach to prevent recurrent bacterial infections. Read the full story here. https://lnkd.in/ehjCbt4B

Clarametyx COO Dr. Veronica Hall shares her perspective on how the newly announced agreement with CARB-X helps to support our platform strategy and accelerate development in an area of high unmet need in infectious disease. https://lnkd.in/em6azQ85

Wishing a very happy 40th birthday to Emily Kramer-Golinkoff, founder of Emily's Entourage! For those living with cystic fibrosis, milestone birthdays like this aren't taken for granted. This is why we are working hard to develop a new solution that could help reduce the chronic infections that can be life-limiting for this population. If you haven't already, take a look at the incredible work Emily and her team are doing and support them today in her honor.

CARB-X will award US$2.6 million to Clarametyx Biosciences to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program. Clarametyx is developing CMTX-301, a pathogen-agnostic anti-biofilm vaccine candidate designed to prevent bacterial biofilm formation and allow the body’s natural immune response to clear infections. The CARB-X award will advance CMTX-301 from Lead Optimization stage to Preclinical (IND) evaluation. If successful, immunization with CMTX-301 to prevent the occurrence of biofilm-associated infections may decrease the need for antibiotic therapy and thus decrease the threat of resistance development.   This is the second award CARB-X has provided to support Clarametyx’s work on novel anti-biofilm technologies. In 2020, CARB-X funded Clarametyx to advance CMTX-101 to clinical evaluation. CMTX-101 targets the scaffolding protein in biofilms and is intended to be used in combination with antibiotics to effectively treat bacterial infections. The new award will support advancement of CMTX-301. This candidate targets the same scaffolding machinery of the biofilm, however, is designed to prevent biofilm formation to reduce and clear bacterial infection and reduce the need for antibiotic intervention. 🔗 Read more: bit.ly/3W2dvSv #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)

Today we're proud to announce a new grant agreement with CARB-X, which will enable development of our vaccine platform toward Phase 1 clinical studies for chronic bacterial infections. Read today's announcement for more details: https://lnkd.in/em6azQ85

Columbus Business First’s inaugural Innovators in Healthcare and Life Sciences Awards has named Clarametyx leaders to its prestigious list! Congratulations to CEO David V. Richards who is recognized for his executive leadership; to scientific co-founder Dr. Lauren Bakaletz, recognized for her research innovation, and Board member Dr. Michael Triplett, honored for his entrepreneurship. See the full profiles published here:

Exciting news! Clarametyx has been recognized among the most innovative product development companies as part of Columbus Business First’s inaugural Innovators in Healthcare and Life Sciences awards. See the full profile published here: https://lnkd.in/ed7x9MtE

We support the World Health Organization efforts to highlight the daunting challenge of antibiotic resistance during #WorldAMRAwarenessWeek. A wide range of global efforts are underway to address this threat through collaborative research and innovation. #antibioticresistance

We’re honored to be named the “Infectious Disease Innovation of the Year” as part of the 2024 BioTech Breakthrough Awards! This is rewarding recognition for the momentum we are generating with our anti-biofilm antibody approach targeting chronic respiratory disease. See today’s announcement here. https://lnkd.in/e-TTWB6G